L
LJPP
vs
D
DAX Index
Over the past 12 months, LJPP has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +11% growth.
Stocks Performance
LJPP vs DAX Index
Performance Gap
LJPP vs DAX Index
Performance By Year
LJPP vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
La Jolla Pharmaceutical Co
Glance View
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 61 full-time employees. Its product pipeline includes GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shocks. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shocks. Its XERAVA is a tetracycline-class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its early-stage clinical development product candidate includes TP-6076 and TP-2846. Its TP-6076 is an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846 is an IV formulation of tetracycline for the treatment of acute myeloid leukemia. Its product candidate also includes TP-271.
